An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Stanley Cohen, Jose L. Pablos, Karel Pavelka, Gerard Anton Müller, Alan Matsumoto, Alan Kivitz, Hui Wang, Eswar Krishnan

ABSTRACT

BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). METHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. RESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. CONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. TRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931. More... »

PAGES

84

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3

DOI

http://dx.doi.org/10.1186/s13075-019-1857-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113057001

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30922373


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Metroplex Clinical Research Center", 
          "id": "https://www.grid.ac/institutes/grid.477482.a", 
          "name": [
            "Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, 75231, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Stanley", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario 12 De Octubre", 
          "id": "https://www.grid.ac/institutes/grid.144756.5", 
          "name": [
            "Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pablos", 
        "givenName": "Jose L.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Revmatologick\u00fd \u00fastav", 
          "id": "https://www.grid.ac/institutes/grid.418965.7", 
          "name": [
            "Institute of Rheumatology, Prague 2, Czech Republic"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavelka", 
        "givenName": "Karel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Abteilung.f\u00fcr Nephrologie und Rheumatologie, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "M\u00fcller", 
        "givenName": "Gerard Anton", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Arthritis and Rheumatism Associates", 
          "id": "https://www.grid.ac/institutes/grid.490547.b", 
          "name": [
            "Arthritis and Rheumatism Associates, Wheaton, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumoto", 
        "givenName": "Alan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Abteilung f\u00fcr Nephrologie und Rheumatologie, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kivitz", 
        "givenName": "Alan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Hui", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krishnan", 
        "givenName": "Eswar", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/rheumatology/ket260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000218995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.22214", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009901742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2016.01.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012251139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ker124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012965699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/1744666x.2015.1090313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013216059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017993092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-209166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023109204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar3147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024364202", 
          "https://doi.org/10.1186/ar3147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2016.01.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032526040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2015.04.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037699729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0184-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038300105", 
          "https://doi.org/10.1007/s40259-016-0184-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0184-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038300105", 
          "https://doi.org/10.1007/s40259-016-0184-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-016-0601-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040002812", 
          "https://doi.org/10.1007/s11926-016-0601-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-016-0601-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040002812", 
          "https://doi.org/10.1007/s11926-016-0601-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042463549", 
          "https://doi.org/10.1007/s40259-016-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042463549", 
          "https://doi.org/10.1007/s40259-016-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0049-0172(90)90060-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045775208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078771680", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2016.12.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084083514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-017-0218-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050557", 
          "https://doi.org/10.1007/s40259-017-0218-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-017-0218-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050557", 
          "https://doi.org/10.1007/s40259-017-0218-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-210459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085872012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.15857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090920617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.15857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090920617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1106025459", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).\nMETHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40\u2009mg ABP 501 every other week for 68\u2009weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline.\nRESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade\u2009\u2265\u20093 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was -\u20092.25 at the OLE study baseline (n\u2009=\u2009440), -\u20092.36 at week 4 (n\u2009=\u2009463), -\u20092.41 at week 24 (n\u2009=\u2009450), -\u20092.55 at week 48 (n\u2009=\u2009433), and -\u20092.60 at week 70 (n\u2009=\u2009412). Efficacy was maintained throughout the study.\nCONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity.\nTRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13075-019-1857-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis", 
    "pagination": "84", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13075-019-1857-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113057001"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9c2f7819fbddef15635892850b461d152ea07841efcdb7f2f174243af446fe38"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101154438"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30922373"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13075-019-1857-3", 
      "https://app.dimensions.ai/details/publication/pub.1113057001"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106834_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13075-019-1857-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      49 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13075-019-1857-3 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nd4d132f40c2540328a0e3abdf8b35650
4 schema:citation sg:pub.10.1007/s11926-016-0601-0
5 sg:pub.10.1007/s40259-016-0184-3
6 sg:pub.10.1007/s40259-016-0185-2
7 sg:pub.10.1007/s40259-017-0218-5
8 sg:pub.10.1186/ar3147
9 https://app.dimensions.ai/details/publication/pub.1078771680
10 https://app.dimensions.ai/details/publication/pub.1106025459
11 https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w
12 https://doi.org/10.1002/art.22214
13 https://doi.org/10.1016/0049-0172(90)90060-s
14 https://doi.org/10.1016/j.jaad.2016.12.014
15 https://doi.org/10.1016/j.semarthrit.2015.04.002
16 https://doi.org/10.1016/j.semarthrit.2016.01.001
17 https://doi.org/10.1016/j.semarthrit.2016.01.002
18 https://doi.org/10.1093/rheumatology/ker124
19 https://doi.org/10.1093/rheumatology/ket260
20 https://doi.org/10.1111/bjd.15857
21 https://doi.org/10.1136/annrheumdis-2016-209166
22 https://doi.org/10.1136/annrheumdis-2016-210459
23 https://doi.org/10.1586/1744666x.2015.1090313
24 schema:datePublished 2019-12
25 schema:datePublishedReg 2019-12-01
26 schema:description BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). METHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. RESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. CONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. TRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931.
27 schema:genre research_article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf Nd2c54526ab434cf8bb866ed5adc58dc6
31 Ne4068f2eb06449d1a7d768ffa576b710
32 sg:journal.1297499
33 schema:name An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
34 schema:pagination 84
35 schema:productId N013ef8b618f5466faaea8de362c327ad
36 Na3b97a0a5d894f75b9408ed8b541d7db
37 Nca6ea072d2474f4caa718feadbb6a12f
38 Nd540efd1c5e142f19d368b4ac28acb0f
39 Ne1fc849c7cd44ccd964f3e25c16aab98
40 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113057001
41 https://doi.org/10.1186/s13075-019-1857-3
42 schema:sdDatePublished 2019-04-16T06:25
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher N664efecfec3149b094752b76b98b74d1
45 schema:url https://link.springer.com/10.1186%2Fs13075-019-1857-3
46 sgo:license sg:explorer/license/
47 sgo:sdDataset articles
48 rdf:type schema:ScholarlyArticle
49 N013ef8b618f5466faaea8de362c327ad schema:name nlm_unique_id
50 schema:value 101154438
51 rdf:type schema:PropertyValue
52 N0424a66ab9ea40599b84ec2e8a2707c6 rdf:first Ne0188322064b4a4f85e172b7e9f79c25
53 rdf:rest Ne2668def12f948eaa8eba4655ebf9403
54 N08e0b9e71dac45498def28df9cbfaebe schema:affiliation https://www.grid.ac/institutes/grid.144756.5
55 schema:familyName Pablos
56 schema:givenName Jose L.
57 rdf:type schema:Person
58 N10ee644c83e74ec99a7e1e28b3ac4eb4 rdf:first N98108b2d42f446cb842576d773dfc91d
59 rdf:rest N0424a66ab9ea40599b84ec2e8a2707c6
60 N16a2bebbd856488b96dfa8092a2846e0 schema:affiliation https://www.grid.ac/institutes/grid.490547.b
61 schema:familyName Matsumoto
62 schema:givenName Alan
63 rdf:type schema:Person
64 N1ab47c43f09745f7aebb9412e3ff34f7 rdf:first N08e0b9e71dac45498def28df9cbfaebe
65 rdf:rest N10ee644c83e74ec99a7e1e28b3ac4eb4
66 N59787577f7fd42fb8e1a35d51783a269 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
67 schema:familyName Krishnan
68 schema:givenName Eswar
69 rdf:type schema:Person
70 N664efecfec3149b094752b76b98b74d1 schema:name Springer Nature - SN SciGraph project
71 rdf:type schema:Organization
72 N73f6f3821c594d719cc74a265d075a22 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
73 schema:familyName Wang
74 schema:givenName Hui
75 rdf:type schema:Person
76 N86985cd9bb3c4636813c3c044d05a393 rdf:first Nea6120c91fb94115ad5553e0d4c814f8
77 rdf:rest N86c8807143d34ce8b8a2e703f1beacb6
78 N86c8807143d34ce8b8a2e703f1beacb6 rdf:first N73f6f3821c594d719cc74a265d075a22
79 rdf:rest Nc0e93ab60ba747688d3eb87b564648e9
80 N98108b2d42f446cb842576d773dfc91d schema:affiliation https://www.grid.ac/institutes/grid.418965.7
81 schema:familyName Pavelka
82 schema:givenName Karel
83 rdf:type schema:Person
84 Na3b97a0a5d894f75b9408ed8b541d7db schema:name doi
85 schema:value 10.1186/s13075-019-1857-3
86 rdf:type schema:PropertyValue
87 Nc0e93ab60ba747688d3eb87b564648e9 rdf:first N59787577f7fd42fb8e1a35d51783a269
88 rdf:rest rdf:nil
89 Nc8a807ed5ed64a9995dacc85e05adb00 schema:affiliation https://www.grid.ac/institutes/grid.477482.a
90 schema:familyName Cohen
91 schema:givenName Stanley
92 rdf:type schema:Person
93 Nca6ea072d2474f4caa718feadbb6a12f schema:name dimensions_id
94 schema:value pub.1113057001
95 rdf:type schema:PropertyValue
96 Nd2c54526ab434cf8bb866ed5adc58dc6 schema:volumeNumber 21
97 rdf:type schema:PublicationVolume
98 Nd4d132f40c2540328a0e3abdf8b35650 rdf:first Nc8a807ed5ed64a9995dacc85e05adb00
99 rdf:rest N1ab47c43f09745f7aebb9412e3ff34f7
100 Nd540efd1c5e142f19d368b4ac28acb0f schema:name readcube_id
101 schema:value 9c2f7819fbddef15635892850b461d152ea07841efcdb7f2f174243af446fe38
102 rdf:type schema:PropertyValue
103 Ne0188322064b4a4f85e172b7e9f79c25 schema:affiliation Ne3ac661479a249a783f5b6ef36256f93
104 schema:familyName Müller
105 schema:givenName Gerard Anton
106 rdf:type schema:Person
107 Ne1fc849c7cd44ccd964f3e25c16aab98 schema:name pubmed_id
108 schema:value 30922373
109 rdf:type schema:PropertyValue
110 Ne2668def12f948eaa8eba4655ebf9403 rdf:first N16a2bebbd856488b96dfa8092a2846e0
111 rdf:rest N86985cd9bb3c4636813c3c044d05a393
112 Ne3ac661479a249a783f5b6ef36256f93 schema:name Abteilung.für Nephrologie und Rheumatologie, Göttingen, Germany
113 rdf:type schema:Organization
114 Ne4068f2eb06449d1a7d768ffa576b710 schema:issueNumber 1
115 rdf:type schema:PublicationIssue
116 Nea6120c91fb94115ad5553e0d4c814f8 schema:affiliation Nf0ff144ecdb844c2a058952dc9d07aa9
117 schema:familyName Kivitz
118 schema:givenName Alan
119 rdf:type schema:Person
120 Nf0ff144ecdb844c2a058952dc9d07aa9 schema:name Abteilung für Nephrologie und Rheumatologie, Göttingen, Germany
121 rdf:type schema:Organization
122 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
123 schema:name Medical and Health Sciences
124 rdf:type schema:DefinedTerm
125 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
126 schema:name Clinical Sciences
127 rdf:type schema:DefinedTerm
128 sg:journal.1297499 schema:issn 1478-6354
129 1478-6362
130 schema:name Arthritis Research & Therapy
131 rdf:type schema:Periodical
132 sg:pub.10.1007/s11926-016-0601-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040002812
133 https://doi.org/10.1007/s11926-016-0601-0
134 rdf:type schema:CreativeWork
135 sg:pub.10.1007/s40259-016-0184-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038300105
136 https://doi.org/10.1007/s40259-016-0184-3
137 rdf:type schema:CreativeWork
138 sg:pub.10.1007/s40259-016-0185-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042463549
139 https://doi.org/10.1007/s40259-016-0185-2
140 rdf:type schema:CreativeWork
141 sg:pub.10.1007/s40259-017-0218-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085050557
142 https://doi.org/10.1007/s40259-017-0218-5
143 rdf:type schema:CreativeWork
144 sg:pub.10.1186/ar3147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024364202
145 https://doi.org/10.1186/ar3147
146 rdf:type schema:CreativeWork
147 https://app.dimensions.ai/details/publication/pub.1078771680 schema:CreativeWork
148 https://app.dimensions.ai/details/publication/pub.1106025459 schema:CreativeWork
149 https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1017993092
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1002/art.22214 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009901742
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1016/0049-0172(90)90060-s schema:sameAs https://app.dimensions.ai/details/publication/pub.1045775208
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1016/j.jaad.2016.12.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084083514
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1016/j.semarthrit.2015.04.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037699729
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1016/j.semarthrit.2016.01.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032526040
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/j.semarthrit.2016.01.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012251139
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1093/rheumatology/ker124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012965699
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1093/rheumatology/ket260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000218995
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1111/bjd.15857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090920617
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1136/annrheumdis-2016-209166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023109204
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1136/annrheumdis-2016-210459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085872012
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1586/1744666x.2015.1090313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013216059
174 rdf:type schema:CreativeWork
175 https://www.grid.ac/institutes/grid.144756.5 schema:alternateName Hospital Universitario 12 De Octubre
176 schema:name Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
177 rdf:type schema:Organization
178 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
179 schema:name Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA
180 rdf:type schema:Organization
181 https://www.grid.ac/institutes/grid.418965.7 schema:alternateName Revmatologický ústav
182 schema:name Institute of Rheumatology, Prague 2, Czech Republic
183 rdf:type schema:Organization
184 https://www.grid.ac/institutes/grid.477482.a schema:alternateName Metroplex Clinical Research Center
185 schema:name Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, 75231, Dallas, TX, USA
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.490547.b schema:alternateName Arthritis and Rheumatism Associates
188 schema:name Arthritis and Rheumatism Associates, Wheaton, MD, USA
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...